• R-Biopharm AG
  • Contact
  • Media
  • Online Seminars
  • Events
Languages
  • English
  • Español
  • Deutsch
  • Français
  • Italiano
  • Nederlands
Subscribe
  • Start
  • Diagnostics
    • Allergology
    • Bacteriology
    • Gastroenterology
    • Human genetics
    • Mycology
    • Parasitology
    • Syndromic Testing
    • Tuberculosis
    • Virology
  • Indication
    • Allergies
    • Dermatophyte Infections
    • Gastrointestinal infections
    • Hospital aquired infections and drug resistance
    • Respiratory infections
    • Sexually transmitted infections
    • Therapeutic drug monitoring
    • Vector-borne infections
  • Technologies
    • Immunoblot
    • ELISA
    • Real-time PCR
    • Rapid tests
    • Quality Assessment Products
    • MT-PCR
  • Systems
  • Product Finder
  • News
  • Shop
A Division of the R-Biopharm Group
  • Start
  • Diagnostics
    • Allergology
    • Bacteriology
    • Gastroenterology
    • Human genetics
    • Mycology
    • Parasitology
    • Syndromic Testing
    • Tuberculosis
    • Virology
  • Indication
    • Allergies
    • Dermatophyte Infections
    • Gastrointestinal infections
    • Hospital aquired infections and drug resistance
    • Respiratory infections
    • Sexually transmitted infections
    • Therapeutic drug monitoring
    • Vector-borne infections
  • Technologies
    • Immunoblot
    • ELISA
    • Real-time PCR
    • Rapid tests
    • Quality Assessment Products
    • MT-PCR
  • Systems
  • Product Finder
  • News
  • Shop

Diagnostics

Home » Diagnostics » Page 7
Drug monitoring of infliximab biosimilars

Drug monitoring of infliximab biosimilars

Ann Gils and her colleagues from KU Leuven evaluated if the biosimilars were equally well quantified as the original infliximab (IFX) drug in their clinically validated infliximab assay.

READ MORE
Legionella and mycoplasma pneumoniae: New RIDA®GENE products for detection of atypical CAP bacteria

Legionella and mycoplasma pneumoniae: New RIDA®GENE products for detection of atypical CAP bacteria

Community-acquired pneumonia (CAP) is the most common fatal infectious disease in western countries. Bacteria are the most common pathogens causing CAP, where one differentiates between typical [...]

READ MORE
Therapeutic drug monitoring of Infliximab

Therapeutic drug monitoring of Infliximab

RIDASCREEN® IFX Monitoring is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, anti-TNFα) in human serum and plasma. 

READ MORE
New: RIDA®GENE Parainfluenza

New: RIDA®GENE Parainfluenza

Human parainfluenza viruses (HPIV) can cause both upper respiratory infections and lower respiratory infections.

READ MORE
RIDA®GENE Enterovirus: New real-time RT-PCR assay

RIDA®GENE Enterovirus: New real-time RT-PCR assay

RIDA®GENE Enterovirus – the new real-time RT-PCR assay for the detection of the major human enteroviruses

READ MORE
Pancreatic insufficiency in diabetes & mucoviscidosis patients

Pancreatic insufficiency in diabetes & mucoviscidosis patients

About 50 % of Type-1-Diabetics, 33 % Type-2-Diabetics and 75 – 80 % Mucoviscidosis patients develop exocrine pancreatic insufficiency in the course of their illness (Hardt PD, [...]

READ MORE
RIDA qLine® Allergy: The next generation of allergy in-vitro diagnostics

RIDA qLine® Allergy: The next generation of allergy in-vitro diagnostics

R-Biopharm AG has faced the challenge to develop a sophisticated allergy in vitro test system that combines both a quantitative determination and a very economic and easy handling.

READ MORE
New rapid test format of RIDA®QUICK Norovirus available

New rapid test format of RIDA®QUICK Norovirus available

READ MORE
New line blot immunoassays: RIDA®LINE Helicobacter IgG & lgA

New line blot immunoassays: RIDA®LINE Helicobacter IgG & lgA

New line blot immunoassays – reliable differentiation between human IgG and IgA antibodies against Helicobacter pylori type I and II strains

READ MORE
Fastest of its kind: New molecular biological test for the specific detection of EHEC bacteria

Fastest of its kind: New molecular biological test for the specific detection of EHEC bacteria

R-Biopharm (Darmstadt) has brought to the market the fastest assay currently available for the specific detection of enterohemorrhagic Escherichia coli (EHEC). With the new RIDA®GENE EHEC/EPEC [...]

READ MORE
1 2 3 4 5 6 7 8
page 1 of 8

Clinical Diagnostics

A division of R-Biopharm AG
Company information
  • R-Biopharm AG
  • An der Neuen Bergstraße 17
    64297 Darmstadt, Germany
  • +49 (0) 61 51 - 81 02-0
  • +49 (0) 61 51 - 81 02-40
  • info@r-biopharm.de
  • www.r-biopharm.com
Copyright All Rights Reserved ©
  • Imprint
  • Privacy policy
  • GTCs
  • GTCs (Purchase)

Start typing and press Enter to search